Resumen de Investigación
Analyzed using Evidence Intelligence™

Hybrid telemedicine improves glycemic control in type 1 diabetes

Última actualización 8 de julio de 2026

Key finding

A1c levels significantly decreased from 6.9 ± 0.5% at baseline to 6.7 ± 0.5% after 12 months.

This study evaluated a hybrid telemedicine approach for adults with type 1 diabetes against standard clinical practice, finding a significant reduction in HbA1c levels.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Long-Term (1–5 y)

Risk of bias

Some Concerns

Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

This study evaluated a hybrid telemedicine approach for adults with type 1 diabetes against standard clinical practice, finding a significant reduction in HbA1c levels.

Clinical relevance

This research highlights the potential of telemedicine in diabetes management, particularly for individuals who may benefit from reduced in-person visits. The significant reduction in HbA1c suggests that such approaches can maintain or improve glycemic control, which is crucial for long-term health in diabetes patients.

Keep in mind

No specific results reported for glycemic variability. Limited information on time below target range. Effectiveness of the hybrid approach remains unclear for some outcomes.

Published in

Referencia de la Revista

Publication details and source links for this paper.

Lía N, Esther DLC, Edurne L, et al. A hybrid telemedicine approach for adults with type 1 diabetes using an advanced closed-loop system: a randomized clinical trial. Therapeutic Advances in Endocrinology and Metabolism. 2024;15:20420188241288789. doi:10.1177/20420188241288789

Efectos Principales

HbA1c levels decreased from 6.9% to 6.7% after 12 months (p=0.006).

No statistically significant differences in quality of life were found.

No increase in adverse events was reported despite fewer in-person visits.

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Hybrid closed-loop system and Adverse events incidence, Glucose variability, HbA1c, and 2 more.

Primary intervention

Hybrid closed-loop system

Primary outcomes

  • Adverse events incidence
  • Glucose variability
  • HbA1c

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

5
Evidence pairs
5
Relationships
3
Evidence topics
contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 68

3

Related topics

5

Evidence pairs

876

Related studies

High relevance in at least one topic

Why it is useful

  • Contributes to 5 evidence relationships
  • Includes primary outcome data
  • Linked to 3 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Agrega evidencia relacionada a tu Evidence Tracker

Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.

Evidencia principal

Relación de evidencia

Insulin Delivery Systems and CGM Time in Range

Evidencia relacionada

Relación de evidencia

Insulin Delivery Systems and HbA1c

Guardar evidencia

Relación de evidencia

Insulin Delivery Systems and Glucose Variability

Guardar evidencia

Core evidence

Study findings

The primary outcomes reported in this study.

Adverse events incidence

Hybrid closed-loop system → Adverse events incidence

Hybrid closed-loop system → Adverse events incidence

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
50
Neutral
ConsistencyScore™
unclear
Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence Tracker

Glucose variability

Hybrid closed-loop system → Glucose variability

Hybrid closed-loop system → Glucose variability

Evidence Intelligence™
EvidenceScore™
Strong
Score 79 · Based on 4 studies
ImpactScore™
63
Slightly Positive
ConsistencyScore™
35
mixed
Estudios de apoyo: Basado en 4 estudios
Add to Evidence Tracker

HbA1c

Hybrid closed-loop system → HbA1c

Hybrid closed-loop system → HbA1c

Evidence Intelligence™
EvidenceScore™
84
Strong
ImpactScore™
100
Very Positive
ConsistencyScore™
100
consistent
Estudios de apoyo: Basado en 5 estudios
Add to Evidence Tracker

Quality of life

Hybrid closed-loop system → Quality of life

Hybrid closed-loop system → Quality of life

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
50
Neutral
ConsistencyScore™
unclear
Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence Tracker

Time in range

Hybrid closed-loop system → Time in range

Hybrid closed-loop system → Time in range

Evidence Intelligence™
EvidenceScore™
86
Strong
ImpactScore™
79
Positive
ConsistencyScore™
70
generally_consistent
Estudios de apoyo: Basado en 12 estudios
Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

evidence suggest

La Evidencia Sugiere

  • HbA1c levels decreased by 0.2% (p=0.006) with the hybrid approach.
  • Quality of life scores showed no significant differences between groups.
  • No increase in adverse events was noted despite reduced in-person visits.
who this applies

A quién se aplica

  • Adults with type 1 diabetes.
  • Individuals seeking alternatives to standard clinical practice.
keep in mind

Tener en Cuenta

  • The study did not measure all relevant outcomes, such as glycemic variability.
  • Findings may not be generalizable to all populations with diabetes.
  • The long-term effectiveness of the hybrid approach remains to be determined.
between the lines

Entre Líneas

  • No specific results reported for glycemic variability.
  • Limited information on time below target range.
  • Effectiveness of the hybrid approach remains unclear for some outcomes.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

This study contributes to evidence on Insulin Delivery Systems and CGM Time in Range, Insulin Delivery Systems and HbA1c.

Relaciones de evidencia relacionadas

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does Insulin Delivery Systems improve cgm time in range?

Strong Evidence

Insulin Delivery Systems may improve CGM Time in Range.

ConsistencyScore™: Results are generally consistent across studies.

Ranked evidence signals

  1. 1

    Time in range

    EvidenceScore™ Strong | EvidenceScore™ 86.0 | moderate positive | ConsistencyScore™ Generally Consistent | 1 study

Why this answer: This answer is based on 20 supporting studies with generally consistent results and a positive effect signal.

Limitations

  • Population details are unavailable.
20 supporting studiesUpdated: Aug 2026

Does Insulin Delivery Systems improve HbA1c?

Strong Evidence

Insulin Delivery Systems appears to improve HbA1c.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    HbA1c

    EvidenceScore™ Strong | EvidenceScore™ 84.2 | strong positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 14 supporting studies with consistent results and a positive effect signal.

Limitations

  • Population details are unavailable.
14 supporting studiesUpdated: Aug 2026

Does Insulin Delivery Systems improve glucose variability?

Strong Evidence

Insulin Delivery Systems may improve Glucose Variability.

ConsistencyScore™: Results are generally consistent across studies.

Ranked evidence signals

  1. 1

    Glucose variability

    EvidenceScore™ Strong | EvidenceScore™ 79.0 | weak positive | ConsistencyScore™ Mixed | 1 study

Why this answer: This answer is based on 6 supporting studies with generally consistent results and a positive effect signal.

Limitations

  • Population details are unavailable.
6 supporting studiesUpdated: Aug 2026

Does Insulin Delivery Systems improve quality of life outcomes?

Strong Evidence

Insulin Delivery Systems may improve Quality of Life Outcomes.

ConsistencyScore™: Results are generally consistent across studies.

Ranked evidence signals

  1. 1

    Quality of life

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on 5 supporting studies with generally consistent results and a positive effect signal.

Limitations

  • Population details are unavailable.
5 supporting studiesUpdated: Aug 2026
Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Sin anuncios. Sin rastreo.

Centrada en la evidencia, no en la publicidad.

Segura y privada

Tus datos siempre están protegidos.

Siempre al día

Se agregan nuevos estudios todos los días.